- Published at
- by manilatimes.net
negative
negative
News for Kymera Therapeutics, Inc. (KYMR)
- Published at
- by seekingalpha.com
mixedmixedKymera Therapeutics: Plenty Of Potential, But A Long Way From The Finish Line (KYMR)
Kymera has $900 million in cash and no long-term debt, funding operations into mid-2027. Click here to read an analysis of KYMR stock now.- Published at
- by manilatimes.net
mixedmixed- Published at
- by gurufocus.com
positivepositiveRedmile Group, LLC Reduces Stake in Zymeworks Inc
On December 31, 2024, Redmile Group, LLC (Trades, Portfolio) executed a significant transaction involving Zymeworks Inc (ZYME), reducing its holdings by 261,448- Published at
- by gurufocus.com
positivepositive- Published at
- by zacks.com
positivepositiveKymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?
Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.- Published at
- by seekingalpha.com
negativenegativeKymera stock rises after J.P. Morgan event (KYMR:NASDAQ)
Kymera Therapeutics (KYMR) stock surged as the company outlined its 2025 outlook at the J.P. Morgan Healthcare Conference. Read more here.- Published at
- by investing.com
positivepositiveKymera stock surges on product pipeline update By Investing.com
Kymera stock surges on product pipeline update- Published at
- by manilatimes.net
negativenegative- Published at
- by manilatimes.net
negativenegative- Published at
- by gurufocus.com
neutralneutralKymera Therapeutics Inc (KYMR) to Present at J.P. Morgan Healthcare Conference
Kymera Therapeutics Inc (KYMR), a clinical-stage biopharmaceutical company specializing in oral small molecule degrader medicines for immunological diseases, an- Published at
- by gurufocus.com
negativenegativeKymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14
WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. ( KYMR), a clinical-stage biopharmaceutical company advancing a new class of ora- Published at
- by investing.com
neutralneutralCAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors By Investing.com
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors- Published at
- by seekingalpha.com
negativenegativeKymera: Protein Degradation Could Drive Dupixent-Like Value (NASDAQ:KYMR)
Kymera Therapeutics is a biotech company with promising candidates in its pipeline for inflammatory disorders. Read why KYMR stock is a Strong Buy.- Published at
- by benzinga.com
mixedmixedWhy Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Helen Of Troy (NASDAQ:HELE)
Loading... Loading... Shares of Helen of Troy Limited HELE fell sharply during Tuesday's session after the company reported soft first-quarter earnings and low...UQ1.DETNXPSNGXWSNGXRVMDRSLSQUREQLIQLGNNVOSDNVOSMYOLRMRKYMRJMIAN.MXJMIAHYWHTLDHLIOHELEGNLNCYRXCLNNWCLNNCHPT-WTCHPTBPN.MXBPE5.DEBPE.DEBPAQFBP.LBP-B.LBP-A.LBPBEEMWBEEMB1PP34.SAARLO0IJU.L0HKP.L0EE0.L0A6I.L0A4T.L0A44.LPATHP2AT34.SALGVNIZQVFIOM.VINVVYINDV.LCLEUARHHDARHHCRUS.MXCRUSAMC.DEALB.MXALBA1LB34.SA0HYI.L0HC7.L- Published at
- by investing.com
mixedmixedMonte Rosa Therapeutics announces key leadership promotions By Investing.com
Monte Rosa Therapeutics announces key leadership promotions- Published at
- by marketwatch.com
positivepositiveIndaptus Therapeutics Inc. Stock Quote (U.S.: Nasdaq)
INDP | Complete Indaptus Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.- Published at
- by globenewswire.com
neutralneutralKymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
KT-474/SAR444656 (IRAK4) Phase 2 trials for both hidradenitis suppurativa (HS) and atopic dermatitis (AD) planned to start in 4Q23 by partner Sanofi ...- Published at
- by seekingalpha.com
mixedmixedBiohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache (BHVN)
Biohaven stock is not cheap, but the company's team is experienced. Read why investors should not be surprised if the upside momentum continues for BHVN stock.- Published at
- by gurufocus.com
mixedmixedVanguard Health Care Fund Portfolio and Latest Trades
Vanguard Health Care Fund VGHCX portfolio, holdings, 13f and stock news. Updated: 2023-05-01 portfolio, holdings, 13F and news. Updated: 2023-05-01MRKD.BAMRK.SNMRK.PAMRK.MXMRKITCIINCYGNMSFGMABN.MXGMABCHGCYCHGCFALPMYALPMF6MK.DE4519.T4503N.MX300760.SZZTS.MXZTSZOE.DEZLABZEG.DEZ1TS34.SAWXXWYWXIBFWUXIFWUXAYVRNAUTHRUNHD.BAUCBN.MXUCBJYUCBJFUCB.BRSWAVSRPTSNDXSKXJFSGRYSGENRVMDRV6.DERPRXREGN34.SAREGN.MXREGNRCKTRARE.MXRAREPODDPFED.BAPFECL.SNPFE.SNPFE.MXPFE.DEPFEPCVXOSHOPHLYOPHLFNVSN.MXNVSEFNVSD.BANVSNTLANSTGNOVN.SWNKTRN1VS34.SAMRNA.MXMRNAM1RN34.SALZAGYLZAGFLONNN.MXLONN.SWKYMRKRTX.MXKRTXIRWDIQV.MXIQVIMCRILU.DEILMN.MXILMNIDP.DEI1QV34.SAI1LM34.SAHUM.MXHCA.MXHCAH1CA34.SAEVHESALYESALFDXCM.MXDXCMDNLIDC4.DED1EX34.SACRLCLDXBPMCBIIBD.BABIIBCL.SNBIIB.SNBIIB.MXBIIB.BABIIBBAX.MXBAXAZNN.MXAZNCFAZN.LAZNARGX.BRARGXARGNFAPLSALGN.MXALGNABTCL.SNABT.SNABTA1RG34.SAA1LG34.SA6417.T603939.SS603259.SS4528.T4523.T2359.HK2269N.MX0UNL.L0R2M.L0QNO.L0QK8.L0M3Q.L0LIF.L0L35.L0K9E.L0JDM.L0JBU.L0J8Z.L0J6Z.L0J1R.L0HCK.L0A8R.L0A4M.L0A4J.L0A45.L